FATE/BJ-HCC-2 is a newly identified cancer/testis (CT) antigen, which was detected in tumor tissues and testis. As previous studies of FATE/BJ-HCC-2 expression pattern were mainly based on messenger RNA (mRNA) analysis, it is necessary to investigate its actual protein expression pattern in tumor tissues for the evaluation of its application value. In this study, we produced specific polyclonal antibody (pAb) to the recombinant FATE/ BJ-HCC-2 protein and analyzed the FATE/BJ-HCC-2 antigen expression in normal and malignant tissues by the immunohistochemical approach. The results showed that there was no detectable FATE/BJ-HCC-2 antigen expressed in normal tissues except testis. In hepatocellular carcinoma (HCC) tissues, the FATE/BJ-HCC-2 antigen was detected in 20% (7/35) specimens. All samples that expressed the FATE/BJ-HCC-2 antigen were of poorly or moderately differentiated HCC. The stained antigen was located in the cytoplasm and the staining pattern showed heterogeneity from focal to more than 40% of the tumor cells. The FATE/BJ-HCC-2 antigen was also expressed in other tumor tissues. The results of [ 3 H]thymidine incorporation showed that FATE/BJ-HCC-2 protein enhanced tumor cell proliferation after transfection of FATE/BJ-HCC-2 gene in HCC cell line (Po0.01). This effect could be specifically blocked by anti-FATE/BJ-HCC-2 pAb. Serological screening showed that the antibody specific to the FATE/BJ-HCC-2 antigen was detected in 7.7% (4/52) patients. Notably, the four positive patients bore poorly or moderately differentiated HCC. FATE/BJ-HCC-2 mRNA transcript was detected in the peripheral blood mononuclear cells (PBMCs) of 46.67% patients whose resected HCC tissue samples were positive for FATE/BJ-HCC-2 mRNA, which implicated tumor cell dissemination in blood circulation and may relate to the metastasis of HCC. Thus, FATE/BJ-HCC-2 may be a valuable candidate CT antigen for polyvalent vaccines in tumor immunotherapy and an assisting diagnostic marker for prognosis of the disease.
Successful immunotherapy of cancer patients requires the recognition of tumor-associated antigens by the immune system. To identify the tumorassociated antigens capable of eliciting immune responses in autologous host is a major aim of tumor immunology. 1, 2 Taking the advent of the discovery of a large number of tumor-associated antigens over the last decade, the tumor immunotherapy with various strategies has been approached using the identified genes and their encoding proteins. Cancer/testis (CT) antigens are a category of tumor antigens with normal expression restricted to male germ cells in the testis but not in other adult somatic tissues. In malignancy, these genes are demethylated and activated, resulting in CT antigen expression in a proportion of tumors of various histological types. Since their initial identification by T-cell epitope cloning, the list of CT antigens has been greatly expanded through serological analysis of recombinant cDNA expression libraries (SEREX) and differential messenger RNA (mRNA) expression analysis. [3] [4] [5] [6] [7] Most CT antigen genes are localized on the X-chromosome, often clustered as multigene families. These antigens generally elicit spontaneous humoral and cell-mediated immune responses in tumor patients. CT antigens appear to be the ideal tumor-specific antigen in tumor immunotherapy because the spermatogenic cells do not express HLA molecules and are unable to induce autoimmune response in testis. 2 FATE/BJ-HCC-2 was originally identified as a testis-specific gene and we have recently identified it as a CT antigen-encoding gene, which maps to chromosome Xq28. 8, 9 According to the late classification of CT antigens, the FATE/BJ-HCC-2 is nominated as FATE/CT43. 7 We have demonstrated that FATE/BJ-HCC-2 mRNA is highly expressed in hepatocellular carcinoma (HCC) and not in normal tissues except testis by RT-PCR. 8 However, we do not know the extent of FATE/BJ-HCC-2 protein expression, an essential condition for the antigen to elicit immune response in HCC and in other neoplastic tissues. In this study, we have evaluated the FATE/BJ-HCC-2 antigen expression in normal and malignant tissues by immunohistochemical (IHC) assay with a polyclonal antibody (pAb) specific to the recombinant FATE/BJ-HCC-2 protein (anti-FATE/BJ-HCC-2 pAb). In addition, a parallel comparison was made between the expression of the mRNA transcript and the protein of FATE/BJ-HCC-2 in some HCC specimens. The seroreactivity of HCC patients to the recombinant FATE/BJ-HCC-2 protein was screened by Western blotting assay. The correlation between the frequency of FATE/BJ-HCC-2 protein expression in HCC and the differentiation states of HCC was analyzed. We also observed that the FATE/BJ-HCC-2 gene product enhanced cell proliferation in the transfectant HCC cell line (Bel-7402 cell) and detected the FATE/BJ-HCC-2 gene transcript in peripheral blood mononuclear cells (PBMCs) of HCC patients, and analyzed its potential clinical value.
Materials and methods

Preparation of the Recombinant FATE/BJ-HCC-2 Protein
The recombinant FATE/BJ-HCC-2 protein was expressed in prokaryotic system, which was prepared as in the previous report. 10 Production of the pAb to the Recombinant FATE/BJ-HCC-2 Protein Rabbits were immunized four times subcutaneously at 3-week intervals, with 200 mg purified recombinant FATE/BJ-HCC-2 protein in adjuvant for every rabbit. Complete Freund's adjuvant was used for the first-time immunization; in the subsequent immunizations, incomplete Freund's adjuvant (Sigma, St Louis, MO, USA) was used. After the fourth time, the rabbit antisera were tested by solid-phase enzyme-linked immunosorbent assay (ELISA) on microtiter plates coated with the immunizing recombinant FATE/BJ-HCC-2 protein as a target antigen. Titer of antiserum was over 1:20 000. Lysates of Escherichia coli were used to absorb nonspecific antibodies against the residual E. coli components in the rabbit antisera. The anti-FATE/BJ-HCC-2 pAb was purified by a protein A column using the instructions of the manufacturer (Pierce, Rockford, IL, USA). The purified antibody was also absorbed with the FATE/BJ-HCC-2 protein to estimate its specificity in IHC experiments. The final concentration of the pAb for IHC staining was 0.5 mg/ml.
Tissue Sections, Sera and PBMC Samples
Tissues sections were provided by the Departments of Pathology of Peking University Health Science Center and the People's Hospital of Peking University. The specimens consisted of formalin-fixed, paraffin-embedded tissue blocks and O.C.T.-embedded (TissueTek, Torrance, CA, USA) snap-frozen tissue samples. In all, 5-mm cuts were made from paraffin or frozen blocks and applied to histology slides for IHC staining. Paraffin sections were dried for 1 h at 801C. A panel of normal and neoplastic tissues was tested as indicated in Tables 1-3 . Since paraffin-embedded specimens represent the standard archival material readily available for antigen expression studies, our analysis concentrated on formalin-fixed, paraffin-embedded tissues. However, for specificity analysis, partial HCC tissues were frozen specimens used for immunohistochemistry and mRNA detection.
The sera and the PBMC samples of HCC patients were from the People's Hospital of Peking University. The sera in this study were not of the same batch as in our previous studies of Dong et al.
8
Patients agreed to the collection of blood and tissue samples with written consent and this was permitted by the Hospital Ethic Review Committee.
IHC Staining
Sections were deparaffinized and rehydrated with xylene and a series of grades of alcohol. Epitope retrieval was carried out in 10 mM citrate buffer (pH 6.0) or 1 mM EDTA buffer (pH 8.0) for 15 min at 951C in a microwave cooker, followed by cooling for 30 min at room temperature. After inactivation of endogenous peroxidase with H 2 O 2 , sections were blocked with 10% normal goat serum for 30 min and then incubated with the anti-FATE/BJ-HCC-2 pAb at room temperature for 1 h. After washing, horseradish peroxidase (HRP)-conjugated anti-rabbit IgG (Zymed laboratories, Inc., South San Francisco, CA, USA) was added and further incubated for 20 min at room temperature. The slides were washed, and diaminobenzidine tetrahydrochloride was then added as a chromogen (Zhongshan Biotech Corp., Beijing), followed by counterstaining with hematoxylin solution. Sections of normal human testis were used as positive control. An unrelated rabbit IgG at the same concentration was used as a negative control. The anti-FATE/BJ-HCC-2 pAb after neutralization with the FATE/BJ-HCC-2 protein served as another control to confirm the specificity of staining. IHC staining of positive samples was repeated twice.
RT-PCR
To determine the specificity of the anti-FATE/ BJ-HCC-2 pAb, RT-PCR analysis and IHC staining of the FATE/BJ-HCC-2 protein were compared in partial HCC samples. RT-PCR was carried out as previously described. 8 Briefly, total RNA was extracted from frozen tissue samples of HCC. Testicular tissue was used as a positive control tissue. RNA was reversely transcribed with AMV reverse transcriptase and oligo dT(18) (Clontech, Palo Alto, CA, USA). The cDNA from testis was used as a positive control. The integrity and quality of the cDNA were confirmed by PCR for G3PDH. Gene-specific PCR primers used to amplify FATE/BJ-HCC-2 were designed according to its sequences (forward: ctg ttc ctg gca ccc tgt gca tcc; reverse: gat gcc gcc atg ctg ttc acc c).
RT-PCR was performed with the Advantage Taq DNA polymerase (Clontech) for 30 cycles in GeneAmp PCR system 9700 (Applied Biosystems, Foster, CA, USA) at an annealing temperature of 661C. Products were analyzed on 1.2% agarose gels containing 0.01 mg/ml ethidium-bromide. The relative quantity of RT-PCR products of mRNA in tumor tissues was assessed by a Bio-Rad Quantity One-4.3.0 analytic system.
For detecting FATE/BJ-HCC-2 gene transcript in PBMCs, total RNA was extracted from freshly isolated PBMCs using TRIzol reagent according to the manufacturer's instructions (Invitrogen, Carlsbad, CA, USA). The cDNA synthesis from total RNA was the same as that described above. The nested PCR amplifications were performed under the following conditions: (1) The cDNA samples from PBMCs were denatured at 941C for 3 min followed by 941C for 30 s, 631C for 30 s, and 721C for 30 s for 30 cycles. The primers were as follows: forward, 5 0 -AGG AGG CCC TCC CAA CAC CAA G-3 0 and reverse, 5 0 -GCA CGG CGA TGA TCA GGG TCTC-3 0 , (2) For the second round of PCR, 2.5 ml of a 1:10 dilution of the first-round PCR product was used as template to amplify FATE/BJ-HCC-2 cDNA. The inner primers were: forward, 5 0 -CGG AGA TGG AAA TGT CCC TGG CAG-3 0 ; reverse, 5 0 -GAC GCC GGT TGA CTG CAT ACA GC-3 0 , which were designed with Gene Runner analysis software 3.04 (Hastings Software Inc.). After initial heating at 941C for 3 min, 30 cycles of PCR were carried out for the amplification (941C for 30 s, 651C for 30 s, and 721C for 30 s).
Transfection of FATE/BJ-HCC-2 Gene in HCC Cell Line
The HCC cell line (Bel-7402 cell) was maintained in our laboratory. The pcDNA3 plasmid was from the 
Transfer of Antibody into Transfectant Cells by Electroporation
The stably transfected Bel-7402 and mock control cells were digested and washed twice with serumfree medium. In all, 6 Â 10 5 cells were incubated with 1 mg/ml anti-FATE/BJ-HCC-2 pAb in 0.6 ml serum-free medium for 10 min on ice. Then the cells in 0.2 cm Bio-Rad electrode gap cuvettes were exposed to a single brief electric pulse of 120 V and a duration of 20 ms delivered from Bio-Rad Gene Pulser (Bio-Rad Laboratories, Hercules, CA, USA) at room temperature. 
Statistical Analysis
The results were expressed as mean7standard error of the mean. The statistical significance was determined by applying a two-tailed Student's t-test. p-valueso0.05 were considered as statistically significant.
Western Blotting
The humoral immune response against the FATE/ BJ-HCC-2 antigen in HCC patients was screened by Western blotting assay. Briefly, the purified FATE/ BJ-HCC-2 protein was separated on 10% SDSpolyacrylamide gel through electrophoresis and transferred onto nitrocellulose membranes. After blocking with 5% skim milk in the TNT buffer (20 mM Tris-HCl, 100 mM NaCl, 0.05% Tween 20, pH 7.5), the membranes were sequentially incubated with HCC patients' sera of a 1:500 dilution for 1 h, then incubated with goat anti-human IgG (H þ L) alkaline phosphatase conjugate (Promega corporation, Madison, WI, USA) for 1 h, and color substrate NBT/BCIP (Promega) was added for color development. To test the specificity of antibody response against the FATE/BJ-HCC-2 protein, the irrelevant protein expressed in E. coli was applied as control in Western blot assay, in which the antibody was only detected against FATE/BJ-HCC-2, but not to irrelevant protein. Figure 1a ). In the seminiferous tubules, the staining was most intense in spermatogonia and in primary spermatocytes; however, at the later stages of maturation, the staining intensity of spermatocytes became weak gradually, and matured spermatids were negative. The staining pattern of the FATE/BJ-HCC-2 antigen was cytoplasmic. Sertoli cells were also strongly immunoreactive (Figure 1a) . No positive staining was found in ovary tissues and other normal tissue samples. However, in the paraffin sections of the pancreas, the Langerhans' cell islets were faintly stained when citrate was used as the antigen retrieval solution. This immunoreactivity of nontesticular normal tissues was absent when EDTA was employed as the antigen retrieval solution, while the staining of testicular tissue stably existed. Hence, EDTA should be used as the antigen retrieval solution in the staining of paraffin sections to reduce or remove nonspecific reactivity. 11 
Results
Distribution of the FATE/BJ-HCC-2 Antigen in Normal Tissues
IHC Analysis in HCC
The expression of the FATE/BJ-HCC-2 antigen in 35 HCC samples is summarized in Table 2 . The overall positive rate of FATE/BJ-HCC-2 antigen expression was 20% (seven of 35). Notably, the proportion of FATE/BJ-HCC-2 antigen expression was reversely correlated with the HCC differentiated states. Higher frequency of FATE/BJ-HCC-2 antigen expression was seen in poorly or moderately differentiated HCC. The positive rate was 30.8% (four of 13) in moderately differentiated HCC and 25.0% (three of 12) in the poorly differentiated HCC, but there was no antigen expression to be detected (0/10) in welldifferentiated HCC. Among different HCC samples, only the cancer cells were observed to be positive by IHC staining with the anti-FATE/BJ-HCC-2 pAb. The staining intensity varied from weak to strong, and the staining pattern showed a high heterogeneity from focal to more than 40% of the cancer cells (Figure 2b and c). The antigen was located in cytoplasm shown by IHC assay. To verify the specificity of IHC staining, sections cut from FATE/BJ-HCC-2-positive samples were stained with the FATE/BJ-HCC-2 proteinabsorbed anti-FATE/BJ-HCC-2 pAb, and exhibited IHC negative. Thus, the positive IHC staining specifically manifested the expression of the FATE/ BJ-HCC-2 antigen in HCC samples.
Correlativity of the Expression of the FATE/BJ-HCC-2 Protein and mRNA in HCC Samples
To further confirm the specificity of the anti-FATE/ BJ-HCC-2 antibody, the expression of the FATE/ BJ-HCC-2 protein and mRNA in HCC samples was compared. The FATE/BJ-HCC-2 mRNA expression was detected in 66% tumor samples as mentioned in our previous report. 8 In this study, 15 HCC samples were available for both mRNA and protein analysis in parallel. Of these, three samples were both FATE/ BJ-HCC-2 protein positive as displayed by IHC staining and mRNA positive assessed by RT-PCR; seven samples were mRNA positive but protein negative in IHC staining; all these seven samples exhibited lower copies of mRNA shown in the relative quantitative analysis of PCR products ( Figure  2a and b) ; five samples were negative for both protein and mRNA. None of the FATE/BJ-HCC-2 mRNAnegative samples expressed the FATE/BJ-HCC-2 
Analysis of FATE/BJ-HCC-2 antigen expression XA Yang et al protein, indicating the specificity of IHC staining in HCC with the anti-FATE/BJ-HCC-2 pAb. (Figure 3 ).
Immunohistochemical Analysis of FATE/BJ-HCC-2 Antigen Expression in Other Malignant Tumors
FATE/BJ-HCC-2 mRNA Expression in PBMCs
With nested PCR amplification, the positive rate of FATE/BJ-HCC-2 mRNA transcript in PBMCs of the patients whose resected HCC tissue samples were positive for FATE/BJ-HCC-2 mRNA was 46.67% (Table 4) . FATE/BJ-HCC-2 mRNA transcript was not detected in the PBMCs of the patients whose resected HCC tissue samples were negative for FATE/BJ-HCC-2 mRNA, or in the PBMC of normal donors. In light of the clinical data of the seven positive samples, four patients were classified as being in clinical phase III and three patients were in clinical phase I-II. Of the patients who were followed up, one patient whose PBMCs were positive for FATE/BJ-HCC-2 mRNA transcript, relapsed with metastasis of HCC within 6 months. In comparison, two patients whose PBMCs were negative for FATE/BJ-HCC-2 mRNA transcript did not relapse in 6 months.
Seroreactivity Analysis of Antibody against the FATE/BJ-HCC-2 Protein in HCC Patients
In the 52 sera collected from HCC patients, there were four reactive to the FATE/BJ-HCC-2 protein assessed by Western blotting (Figure 4) . The experiment was repeated twice and the same results were obtained. Thus, the positive rate was 7.7%. As the specific control of seroreactivity, the patient's sera, which were sero-positive to the FATE/BJ-HCC-2 protein, could not react with irrelevant protein. Of note, all these four sero-positive patients had the FATE/BJ-HCC-2 antigen expression in their resected Analysis of FATE/BJ-HCC-2 antigen expression XA Yang et al HCC tissues assessed by IHC analysis. In the analysis of the HCC differentiation states, all these four sero-positive HCC patients bore poorly or moderately differentiated HCC.
Discussion
CT antigens are the most attractive targets for vaccination in tumor immunotherapy, with the potential to eradicate residual tumor cells in multiple sites in cancer patients due to their expression in a variety of tumors but not in normal tissues except testis. 3 In vitro and in vivo experiments have demonstrated that some CT antigens, for example, NY-ESO-1, are capable of provoking potent T-cellmediated immunity to directly kill tumor cells and release cytokines to interfere with the growth of tumor cells, and stimulated antibody response. 12, 13 Promising results have been observed in clinical trials using peptide vaccines derived from CT antigens for tumor immunotherapy. 14, 15 HCC is the third highest cause of cancer death worldwide with a global incidence of 1.2 million new cases per year. The recurrence of HCC after surgical resection is high to 70% and the prognosis of HCC remains poor. Despite many approaches of therapy, such as intra-arterial embolization, chemoembolization, regional chemotherapy, etc, there is no effective systemic therapy for this disease. 16, 17 Immunotherapy may be a promising strategy for HCC treatment. Identification of CT antigens from HCC is definitely needed to find more tumorassociated antigens with good immunogenicity for effective immunotherapy.
FATE/BJ-HCC-2 is a novel CT antigen and the previous analysis of its tissue expression pattern was mainly based on mRNA transcripts. [7] [8] [9] Accurate information on the actual protein expression is a prerequisite for the evaluation of its immunogenicity. For this aim, we have prepared the recombinant FATE/BJ-HCC-2 protein and produced its specific pAb, so as to analyze the FATE/BJ-HCC-2 antigen expression in HCC and other tumor samples. The specificity of the anti-FATE/BJ-HCC-2 pAb was proved by three assays: (1) The pAb only reacted with the FATE/BJ-HCC-2 protein in immunoblotting, 10 not with irrelevant protein. (2) The positive IHC staining was correlated with mRNA expression. (3) The pAb through preabsorption with purified FATE/BJ-HCC-2 protein no more gave IHC-positive staining in the samples, which were positive when stained with the pAb without absorption of specific antigen. With the confirmed specificity of the pAb, the results of IHC staining should be reliable. The FATE/BJ-HCC-2 antigen was expressed in substantial proportion in HCC samples (20%, 7/35) and in melanoma (25%, 2/8) as well as in low proportion in breast cancer (10%, 1/10). The FATE/BJ-HCC-2 antigen was not expressed in colon, prostate and renal cell carcinomas, consistent with a low frequency of CT antigen expression in these tumors. 6, 18 Like other CT antigens, [19] [20] [21] the FATE/BJ-HCC-2 antigen was highly expressed in the testicular tissue. Whereas most CT antigens are only restricted to germ cells, the FATE/BJ-HCC-2 antigen was expressed not only in spermatogonia and the primary spermatocytes but also in Sertoli cells of seminiferous tubule lumen. This may be associated with its function in both germ cells and Sertoli cells. Although we do not know the meaning of its expression in Sertoli cells, the expression of the FATE/BJ-HCC-2 antigen decreased following the maturation process of spermatogenic cells and virtually disappeared in the sperm cells. In addition, FATE/BJ-HCC-2 was coexpressed with SRY gene, which acts as a genetic switch that directs the development of the indifferent gonad from a female to a male pathway. 9 The FATE/BJ-HCC-2 protein may hence function in early testicular differentiation. The expression of FATE/BJ-HCC-2 may also be involved in tumorigenesis as its expression is regulated by steroidogenic factor (SF-1) and Wilms' tumor gene 1 (WT1), the molecules involved in the development of tumors. [22] [23] [24] The [ 3 H]thymidine incorporation assay was used to measure cell DNA synthesis and hence cell proliferation. 25 The results of [ 3 H]thymidine incorporation assay in FATE/ BJ-HCC-2 gene-transfected Bel-7402 cells showed that the FATE/BJ-HCC-2 protein enhanced tumor cell proliferation. This effect was specifically 26, 27 Of the 90 CT antigens identified at present, the biological function of the most of these antigens is unknown except SCP-1, OY-TES-1 and CT15/ Fertilin b. 3, 7 Of course, whether the FATE/BJ-HCC-2 has other functions such as promoting tumor metastasis needs to be further investigated.
In the comparison of mRNA expression with protein expression in HCC samples, all the samples of the FATE/BJ-HCC-2 protein positive in IHC staining were also mRNA positive, detected by RT-PCR. However, the protein expression was determined by the abundance of mRNA copies. In the relative quantitative analysis of RT-PCR products, the FATE/BJ-HCC-2 protein in samples expressed low abundance of mRNA and were unable to be detected by IHC staining.
There are two significant features revealed by IHC staining with the anti-FATE/BJ-HCC-2 pAb. First, the expression of the FATE/BJ-HCC-2 antigen correlated with the differentiation states of the HCC. This antigen is preferentially expressed in moderately and poorly differentiated HCC. Similar results were also shown in NY-ESO-1 expression in melanoma 28 and MAGE-A4 in transitional cell carcinoma. 29 Second, the IHC staining pattern is heterogeneous in different HCC samples, the expression of the FATE/BJ-HCC-2 antigen in tumor cells ranging from focal to a large mass of tumor cells. This heterogeneity appears to be a consistent morphologic characteristic of all CT antigens in many tumor types. 19, 21, 30, 31 This might be associated with spatial and temporal modulation of genes in the advanced tumors. [32] [33] [34] Serological analysis of antibody to the FATE/ BJ-HCC-2 protein showed that 7.7% HCC patients developed spontaneous antibody responses without vaccine immunization. All these sero-positive HCC patients had the antigen expression in their resected HCC tissues. This suggests that the FATE/BJ-HCC-2 antigen is immunogenic as it elicited humoral immune responses in HCC patients. As the CT antigens can provoke CD4 þ and CD8 þ T-cell responses rather than induce antibody response, the availability of the recombinant protein makes us able to measure cellular response specific to this antigen through which to determine if it is a potential tumor antigen for clinical trial.
The high recurrence rate of HCC is probably attributed to the dissemination of tumor cells into blood circulation. Early detection of metastatic tumor cells is critical to identify HCC patients at high risk of relapse and for the prescriptive therapy. 35 Since Smith et al 36 first successfully adopted the RT-PCR technique to assess tyrosinase mRNA as a tumor marker to detect circulating melanoma cells, the gene transcripts of both tissueassociated and tumor-specific markers have been applied in RT-PCR-based diagnosis of micrometastasis of tumor cells in peripheral blood, such as the tyrosinase and MAGE-3 transcripts in melanoma, MAGE-1 and MAGE-3 in HCC, etc. [35] [36] [37] [38] [39] The results in this study showed that the FATE/BJ-HCC-2 gene transcript was positive in PBMCs of 46.67% patients whose resected HCC tumor tissues were positive for FATE/BJ-HCC-2, implying the early dissemination of HCC cells in blood circulation. The FATE/BJ-HCC-2 gene transcript was detected in PBMCs in both the early and late clinical phase of disease. More importantly, one of those patients whose PBMCs sample was positive for FATE/BJ-HCC-2 mRNA, by the clinical data, relapsed with metastasis of HCC within 6 months. Two patients, whose FATE/ BJ-HCC-2 gene transcript was negative in PBMCs, did not relapse in 6 months. Thus, the persistent positivity for this gene transcript in PBMC may be a specific marker for poor prognosis of HCC patients. More patients need to be followed up for a longer term to confirm this phenomenon. Our previous reports also indicated that blood dissemination of tumor cells occurred in the early stage of HCC. 35 Detection of the FATE/BJ-HCC-2 gene transcript in PBMCs by nested PCR may be useful for specifically diagnosing micrometastasis of HCC cells in peripheral blood and benefit the prediction of HCC recurrence and prognosis of the disease after surgical treatment.
In conclusion, we prepared the specific pAb to the FATE/BJ-HCC-2 antigen and demonstrated that this FATE/BJ-HCC-2 antigen expressed in HCC samples in around 20%. This antigen can elicit humoral immune response in HCC patients that makes it a potential candidate to prepare tumor vaccine for immunotherapy of HCC patients provided that this antigen could also provoke CTL immune response. In view of the heterogeneous expression of CT antigens including the FATE/BJ-HCC-2 antigen in cancer tissues, it is necessary to develop polyvalent vaccines to prevent tumor cells escaping from immune attack.
